Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy

References

• Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41–52
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609–17
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97–103
   PubMed Web of Science ®Google Scholar
• Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103–7
   PubMed Web of Science ®Google Scholar
• Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 33: 419–23
   PubMedGoogle Scholar
• Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 1438–47
   PubMed Web of Science ®Google Scholar
• Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28–35
   PubMed Web of Science ®Google Scholar
• Weegink CJ, Sentjens RE, Beld MG, Dijkgraaf MG, Reesink HW. Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study. J Viral Hepatol 2003; 10: 174–82
   PubMedGoogle Scholar
• Sentjens RE, Weegink CJ, Beld MG, Cooreman MC, Reesink HW. Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily. Eur J Gastroenterol Hepatol 2002; 14: 833–40
   PubMedGoogle Scholar
• Rosen HR, Ribeiro RR, Weinberger L, Wolf S, Chung M, Gretch DR, et al. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol 2002; 37: 124–30
   PubMedGoogle Scholar
• Steindl-Munda P, Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, et al. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy. Liver Int 2003; 23: 269–75
   PubMed Web of Science ®Google Scholar
• Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34: 1006–11
   PubMed Web of Science ®Google Scholar
• Yasui K, Okanoue T, Murakami Y, Itoh Y, Minami M, Sakamoto S, et al. Dynamics of hepatitis C viremia following interferon-alpha administration. J Infect Dis 1998; 177: 1475–9
   PubMedGoogle Scholar
• Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149–56
   PubMed Web of Science ®Google Scholar
• Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–52
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: June 10–12, 2002. Hepatology 2002;36 Suppl 1:S3–20.
   PubMedGoogle Scholar
• Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425–33
   PubMed Web of Science ®Google Scholar
• Beld M, Sentjens R, Rebers S, Weegink C, Weel J, Sol C, et al. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol 2002; 40: 788–93
   PubMedGoogle Scholar
• Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000; 38: 4171–9
   PubMedGoogle Scholar
• Ross RS, Viazov SO, Hoffmann S, Roggendorf M. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J Clin Lab Anal 2001; 15: 308–13
   PubMedGoogle Scholar
• Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepatol 2002; 9: 340–5
   PubMed Web of Science ®Google Scholar
• Agresti A, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. Am Statistician 1998; 52: 119–26
   Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–26
   PubMed Web of Science ®Google Scholar
• Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, et al. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepatol 2003; 10: 37–42
   PubMedGoogle Scholar
• Sherman KE, Shire NJ, Rouster SD, Peters MG, Koziel MJ, Chung RT, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005; 128: 313–27
   PubMed Web of Science ®Google Scholar
• Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997–1002
   PubMed Web of Science ®Google Scholar
• Reesink HW, Forestier N, Weegink CJ, Zeuzem S, McNair L, Purdy S, et al. Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a. J Hepatol 2006; 44(Suppl 2)S272
   Google Scholar
• Moucari R, Ripault MP, Oules V, Martinot-Peignoux M, Asselah T, Boyer N, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007; 46(4)596–604
   PubMedGoogle Scholar
• Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 2006; 44: 291–301
   PubMed Web of Science ®Google Scholar
• Moucari R, Ripault MP, Oules V, Martinot-Peignoux M, Asselah T, Boyer N, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007; 46: 596–604
   PubMed Web of Science ®Google Scholar
• Gelderblom HC, Reesink HW, Beld MGHM, Weegink CJ, Jansen PLM, Dijkgraaf MG, et al. Low level HCV viraemia after initial response during antiviral therapy: transcription-mediated amplification predicts treatment failure. Antiviral Ther 2007; 12: 423–27
   PubMedGoogle Scholar
• Vrolijk JM, Bekkering FC, Brouwer JT, Hansen BE, Schalm SW. High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy. J Viral Hepatol 2003; 10: 205–9
   PubMedGoogle Scholar
• McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006; 44: 411–21
   PubMed Web of Science ®Google Scholar
• Kieffer T, Sarrazin C, Miller JK, Traver S, Zhou Y, Bartels D, et al. Combination of telaprevir (VX-950) and peg-IFNalfa suppresses both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14-day phase 1b study. Hepatology ;:A 2006; 44: 222A–3
   Google Scholar
• Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954–60
   PubMed Web of Science ®Google Scholar